Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
14.84
+0.13 (0.85%)
Jul 2, 2025, 4:00 PM - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Travere Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33.33, which forecasts a 124.67% increase in the stock price over the next year. The lowest target is $20 and the highest is $47.
Price Target: $33.33 (+124.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +102.22% | Jul 1, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $35 → $32 | Strong Buy | Maintains | $35 → $32 | +115.71% | Jun 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +102.22% | Jun 11, 2025 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +102.22% | May 16, 2025 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +102.22% | May 2, 2025 |
Financial Forecast
Revenue This Year
405.34M
from 233.18M
Increased by 73.84%
Revenue Next Year
594.71M
from 405.34M
Increased by 46.72%
EPS This Year
-1.03
from -4.08
EPS Next Year
0.60
from -1.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 466.6M | 835.7M | 1.2B | ||
| Avg | 405.3M | 594.7M | 780.4M | ||
| Low | 327.2M | 441.2M | 578.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 100.1% | 106.2% | 99.1% | ||
| Avg | 73.8% | 46.7% | 31.2% | ||
| Low | 40.3% | 8.8% | -2.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.53 | 3.37 | 6.29 | ||
| Avg | -1.03 | 0.60 | 2.46 | ||
| Low | -1.99 | -1.20 | 0.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 942.9% | ||
| Avg | - | - | 308.6% | ||
| Low | - | - | -59.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.